Mirum Pharmaceuticals Files 8-K on Shareholder Votes
Ticker: MIRM · Form: 8-K · Filed: May 30, 2025 · CIK: 1759425
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
TL;DR
Mirum Pharma filed an 8-K for shareholder votes. Keep an eye on governance.
AI Summary
Mirum Pharmaceuticals, Inc. filed an 8-K on May 30, 2025, reporting on matters submitted to a vote of its security holders as of May 29, 2025. The filing details the company's corporate information, including its principal executive offices in Foster City, California, and its fiscal year end of December 31.
Why It Matters
This filing indicates that Mirum Pharmaceuticals held or is reporting on a vote by its shareholders, which could pertain to significant corporate decisions or governance matters.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about significant financial changes or operational risks.
Key Players & Entities
- Mirum Pharmaceuticals, Inc. (company) — Registrant
- May 29, 2025 (date) — Date of earliest event reported
- May 30, 2025 (date) — Date of Report
- Foster City, California (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Mirum Pharmaceuticals' security holders?
The filing does not specify the exact matters voted upon, only that matters were submitted to a vote of security holders.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 29, 2025.
What is the principal executive office address for Mirum Pharmaceuticals, Inc.?
The principal executive offices are located at 989 East Hillsdale Boulevard, Suite 300, Foster City, California 94404.
What is the fiscal year end for Mirum Pharmaceuticals, Inc.?
The fiscal year end for Mirum Pharmaceuticals, Inc. is December 31.
What is the SEC file number for Mirum Pharmaceuticals, Inc.?
The SEC file number for Mirum Pharmaceuticals, Inc. is 001-38981.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding Mirum Pharmaceuticals, Inc. (MIRM).